Tabelecleucel, tab-cel® - Atara Biotherapeutics pipeline - investigational Epstein-Barr virus associated post-transplant lymphoproliferative disease disorder EBV PTLD T-cell immunotherapy


As pioneers in off-the-shelf, allogeneic T-cell immunotherapies, we are interested in exploring ways, through our internal development teams and external partnerships, to further the potential applications of our innovative proprietary technology platform through:

  • Combination with other agents, where the science indicates possibilities for therapeutic synergies
  • Next generation and complimentary technologies in T-cell immunotherapy
  • Biomarkers to facilitate patient selection and track treatment effect
  • Integrating genetic engineering with our allogeneic platform “backbone” for select conditions

We welcome collaboration and licensing opportunities to broadly explore the potential of our technologies, and to help effectively bring transformational therapies to patients. If you would like to discuss partnering with Atara Biotherapeutics, please contact: bd@atarabio.com.